Massachusetts is currently home to 3366 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
NCT04485286
Recruiting
The goal of this study is to investigate the efficacy of [68Ga]CBP8 to detect collagen deposition in radiation induced tissue injury.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/30/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Lung Cancer, Radiation Fibrosis, Radiation Induced Lung Injury, Pancreas Cancer
Register for Updates
A Clinical Trial Evaluating Diets for IBS
NCT05831306
Recruiting
Diet and lifestyle changes are the recommended first line treatments for symptom relief in irritable bowel syndrome (IBS). Currently the only diet that is widely recommended and for which there is good evidence of efficacy in IBS is one low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (low-FODMAP). While effective, the Low-FODMAP diet is burdensome and costly to patients and in clinical practice adherence to FODMAP restriction is less than optimal. Further, patien... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/27/2023
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Irritable Bowel Syndrome
Register for Updates
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
NCT03662126
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Register for Updates
Intrinsic Foot Muscle Strengthening Interventions for Older Adults
NCT05829369
Recruiting
Falls are the leading cause of injury in adults over age 65. Muscle weakness in the foot can lead to foot and toe deformities such as collapsed arches or bunions, which have been found to contribute to falls in adults over age 65. The current research study aims to investigate the effectiveness of two simple and affordable foot strengthening methods that may make a major impact on balance and fall prevention in older adults.
Gender:
All
Ages:
65 years and above
Trial Updated:
04/24/2023
Locations: Springfield College, Springfield, Massachusetts
Conditions: Accidental Fall
Register for Updates
Optetrak Knee System Post Market Clinical Follow-Up
NCT05788757
Recruiting
A Post-Market Domestic (US) and International Data Collection to Assess the Optetrak Knee System
Gender:
All
Ages:
18 years and above
Trial Updated:
04/21/2023
Locations: Fallon Clinic, Worcester, Massachusetts
Conditions: Knee Arthroplasty, Total
Register for Updates
NAD Augmentation in Diabetes Kidney Disease
NCT05759468
Recruiting
A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.
Gender:
All
Ages:
60 years and above
Trial Updated:
04/21/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Type2diabetes, Diabetic Kidney Disease
Register for Updates
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
NCT04150042
Recruiting
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic cancer in patients who have a deleterious or suspected deleterious BRCA1, BRCA2, or PALB2 genetic alteration. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, low-dose I.V. ethanol, vitamin B12b, and vitamin C in association with autologous hematopoietic stem cell infusion. A dose-escalation schedule will be employed fo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/21/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Breast Cancer Metastatic, Breast Cancer Stage IV, Pancreatic Cancer Stage IV, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Adenocarcinoma of the Breast, PALB2 Gene Mutation
Register for Updates
Longitudinal Studies to Identify Biomarkers for Sturge-Weber Syndrome
NCT04717427
Recruiting
Individuals with Sturge-Weber Syndrome (SWS) sometimes have brain involvement which can result in seizures, stroke-like episodes and neurologic deficits. The purpose of this study is to integrate longitudinal clinical data, radiological data, and blood biomarkers of Sturge-Weber syndrome patients. The research aims are: To integrate longitudinal clinical data, radiological data, and blood biomarkers of Sturge-Weber syndrome patients. Identify plasma and imaging biomarkers sensitive to exacerba... Read More
Gender:
All
Ages:
All
Trial Updated:
04/20/2023
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Sturge-Weber Syndrome
Register for Updates
Molecular Analysis of Patients With Neuromuscular Disease
NCT00390104
Recruiting
The purpose of this study is to identify new genes responsible for neuromuscular disorders and study muscle tissue of patient with known neuromuscular disease, as well as their family members. We are interested in recruiting many types of neuromuscular disease including; Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and limb-girdle muscle dystrophy (LGMD). There are still many patients diagnosed with muscular dystrophy with no causative gene implicated in their disease. Usi... Read More
Gender:
All
Ages:
Between 1 week and 100 years
Trial Updated:
04/20/2023
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Limb-girdle Muscular Dystrophy, Neuromuscular; Disorder, Hereditary, Duchenne/Becker Muscular Dystrophy
Register for Updates
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
NCT05796570
Recruiting
The purpose of this study is to examine if it is feasible to administer decitabine and filgrastim after allogenic hematopoietic stem cell transplant (HCT) in children and young adults with myelodysplastic syndrome, acute myeloid leukemia and related myeloid disorders, and if the treatment is effective in preventing relapse after HCT. The names of the study drugs involved in this study are: Decitabine (a nucleoside metabolic inhibitor) Filgrastim (a recombinant granulocyte colony-stimulating fa... Read More
Gender:
All
Ages:
Between 1 year and 39 years
Trial Updated:
04/19/2023
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies, MDS, Inherited Bone Marrow Failure Syndrome, Myeloid Neoplasm, Aml
Register for Updates
EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy
NCT04921787
Recruiting
This study is a multi-site, cluster randomized, two group implementation trial comparing a low- versus high-intensity implementation strategy for supporting hospital-based opioid use disorder treatment (HBOT) in community hospital settings where medication for opioid use disorder (MOUD) treatment has not been implemented.
Gender:
All
Ages:
All
Trial Updated:
04/19/2023
Locations: Boston University, Boston, Massachusetts
Conditions: Substance Use Disorders, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
Register for Updates
A Study of DF6002 Alone and in Combination With Nivolumab
NCT04423029
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2023
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Solid Tumors
Register for Updates